Aim: In premenopausal women, hyper-androgenicity is associated with central obesity and an increased cardiovascular risk. We investigated the effects of dydrogesterone (DYD)(a non-androgenic progestogen) and norethisterone progestogen use to be tailored to the individual to achieve maximal benefits.
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Introduction
Oral estrogen therapy (ET) is associated with a beneficial reduction in total and low density (LDL)-cholesterol and an increase in high density (HDL)-cholesterol, but also a potentially deleterious increase in serum triglycerides suggesting increased lipolytic activity [1] [2] [3] [4] [5] . Recent clinical studies suggest that ET may have beneficial effects on the central body fat [6] that is recognised to accumulate following the menopause [7] and which is associated with increased cardiovascular risk [8] . Similarly, clinical studies in men associate testosterone deficiency with central obesity [9, 10] , with testosterone appearing to reverse this adiposity suggesting that androgen deficiency in men is associated with central obesity [11] . In premenopausal women, hyper-androgenicity is associated with central obesity [12] , which raises concern about the possible androgenic effects of the progestogen component of combined estrogen and progestogen therapy (EPT).
Progestogen is required to protect against uterine carcinoma observed in women with an intact uterus using unopposed estrogen [13] . Progestogens may reduce the beneficial effects of estrogen on the lipid profile but may also be beneficial [14] . The 19-nortestosterone derivatives e.g. norethisterone (NET) possess androgenic properties, whilst the C21 progestogens e.g. dydrogesterone (DYD) are less androgenic [15] . In a pooled analysis of oral EPT, DYD did not oppose the adverse rise in triglycerides or the beneficial rise in HDL-cholesterol seen with ET. NET induced a net reduction in triglycerides but also a net reduction in HDL-cholesterol [14] . Clinical studies examining the effects of EPT on body fat distribution have also suggested beneficial effects [6, [16] [17] [18] .
Fat mass is controlled by the processes of lipogenesis and lipolysis, with the key regulatory enzymes being lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL)
respectively. Most animal and human studies of progestogens, in the presence of estrogen, have shown increased adipose tissue LPL activity [19] [20] [21] [22] [23] [24] [25] , although not all progestogens used in EPT have been studied. There is less data on the effects of progestogens on lipolysis with no clear overall picture having emerged [21, [24] [25] [26] .
Our aim was to investigate effects of a non-androgenic progestogen, DYD, and an androgenic progestogen, NET, on lipogenesis and lipolysis in subcutaneous abdominal adipocytes isolated from women through measurement of LPL and HSL respectively. In addition, we investigated the rate of lipolysis through measurement of the glycerol concentration in the media.
Materials and Methods

Isolation of mature adipocytes
Subcutaneous abdominal adipose tissue was obtained from 12 non-diabetic subjects Adipocytes were isolated using previously described methods [27, 28] and cultured in phenol red-free Dulbecco's modified Eagle's medium (DMEM/F12)(Gibco, UK) with penicillin (100U/ml), streptomycin (100μ/ml) and transferrin (5μ/ml)(Sigma, UK).
Compacted 1ml aliquots of adipocytes (approximately 500,000 cells) were treated with DYD (Solvay Pharmaceuticals, UK) and NET (Sigma, UK) from 10 -9 M to 10 -7 M and maintained for 48 hours. Samples without hormones added were maintained as controls.
Due to the large number of treatments involved, it was not always possible to obtain sufficient material for all of the treatments to be studies in each patient. As previously described, assessment of adipocyte viability, extraction and quantification of protein was performed [27, 28] .
Analysis of samples
Equal amounts of protein for each treatment and control (10-50μg) were analysed using Western blotting as previously described [27, 28] . Primary antibodies against LPL (56kDa)(1 in 5000 with BSA 0.05%; Research Diagnostics Inc, USA) or HSL (84kDa)(1 in 500) [29] were used, with anti-mouse and anti-rabbit secondary antibody respectively (Binding Site, UK). Chemiluminescent detection was then utilised (ECL+ for LPL and ECL for HSL; Amersham Pharmacia Biotech, UK), with quantification of radiographs using Windows: Gelbase/Gelblot (UVP Ltd, UK).
The glycerol concentration in the media samples were analysed in triplicate using a commercially available colourimetric method (Randox Laboratories, UK).
Statistical analysis was undertaken using analysis of variance for the comparison of control against treatment samples.
Results
Effects on LPL protein expression
All concentrations of DYD increased LPL protein expression, with the maximal effect observed at 10 -8 M; mean protein expression relative to control ± standard error; 
Glycerol release studies
Lower glycerol concentrations were detected in the medium compared to control from 10 -9 M to 10 -7 M for both DYD and NET (p>0.05) (data not shown). These data are in agreement with the HSL protein expression studies.
Discussion
We present the first in vitro evidence that DYD and NET have regulatory effects on lipogenesis and lipolysis in subcutaneous abdominal adipocytes isolated from women.
Addition of DYD and NET increased LPL protein expression and reduced HSL protein expression, suggesting increased lipogenesis and reduced lipolysis respectively. These results confirm that progestogens may regulate adipose tissue mass through effects on the net amount of adipose tissue in the adipocyte. Together with evidence that progesterone increases adipocyte number through effects on proliferation and differentiation in rats [30, 31] , our findings suggest that progesterone has a role in the regulation of fat mass. Despite evidence that HT (hormone therapy) does not cause weight gain, many women express concern about gain weight when considering HT [32] . Further information about effects of EPT on body fat may help alleviate some of the fears that women have about weight gain.
The effects of the progestogens on glycerol release, whilst not statistically significant, suggested a trend consistent with the HSL expression studies. The absence of statistical significance might be due to increased cell lysis leading to increased glycerol release and greater variability in the samples. 7 The protein expression studies are in keeping with studies of adipose tissue in intact female rats showing that progesterone alone [19] [20] [21] , and in combination with estrogen, increased LPL activity [19, 22] . Few studies have examined the effects of progesterone on lipolysis in rats although no effect was seen in intact female rats [21] or ovariectomised and adrenalectomised rats [25] . Further work using progesterone both alone and with estrogen, in ovariectomised and adrenalectomised rats [25, [33] [34] [35] , concluded that estrogen is required for the effects of progesterone on lipogenesis and lipolysis to be seen [25] . In our study, estrogen was not added to the isolated adipocytes since the aim was to study the effects of the progestogens alone. The adipocytes had, however, been exposed to estrogen prior to isolation since the cells were obtained from women and even postmenopausal women are recognised to possess measurable plasma and adipose tissue levels of estrogen [36] .
Previous in vivo human work showed that percutaneous progesterone applied to the thigh for 24 hours, during the follicular phase of the menstrual cycle, increased LPL activity in femoral adipose tissue [23] in agreement with our findings. Oral 17β-estradiol (E 2 ), in combination with androgenic progestogens; levonorgestrel or sequential medroxyprogesterone acetate, was found to increase LPL activity significantly in subcutaneous adipocytes from the femoral area, but not to have significant effects in the abdominal area [24] . These results suggest a modulating role for progestogens, since alone E 2 reduces lipogenesis in adipocytes from subcutaneous abdominal [28] and gluteal adipose tissue [39, 40] . The combination of E 2 and levonorgestrel did not significantly alter lipolysis measured by glycerol release [24] suggesting that the progestogen may also modulate the effects of E 2 on lipolysis since E 2 alone has been shown to increase lipolysis in animal [24, [41] [42] and human studies [28] . Work using oral ethinyl estradiol (EE) alone, and in combination with NET, gave differing results [26] that might be due to the doses of estrogen used or the different systemic potencies of E 2 and EE [43] .
In summary, in subcutaneous abdominal adipocytes isolated from women, the progestogens increased LPL protein expression and reduced HSL protein expression relative to control. Similar effects were observed with androgenic NET and nonandrogenic DYD at the concentrations studied despite the differing effects on the lipid profile when each are taken with estrogen as oral EPT [14] . The concentration of progestogen in fat following oral administration is not known, however, and may differ dramatically to the concentrations used and could also differ with the progestogen.
Additional information might be obtained through similar studies using lower hormone concentrations in this adipose tissue depot and also in other adipose tissue depots. The discovery in human adipose tissue of the estrogen receptor (ER) [44] , the progesterone receptor (PR) and its isoforms (PR-A and PR-B) [45] , provides further opportunities to determine how sex steroids influence body fat distribution. Consideration is increasingly been given to the progestogen chosen for combination with estrogen in HT.
Additional work in this area may enable the progestogen in EPT to be further tailored to the individual woman to optimise effects on both the lipid profile and body fat distribution from the perspective of cardiovascular risk. 
